Harmony Biosciences surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting ...

Neurotech Pharmaceuticals’ eye cell therapy implant has faced a setback as the US Food and Drug Administration (FDA) has ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

FDA sets PDUFA Action Date of June 28, 2025 ...

Dizal has submitted sunvozertinib’s new drug application (NDA) to the US Food and Drug Administration (FDA) aiming to secure approval for treating locally advanced or metastatic non-small cell lung ...

must submit an NDS within 12 months of filing a New Drug Application (NDA) in the US. This requirement is established by ...

The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non ...

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...

Area researchers are helping investigate the promise and the perils of psychedelic drugs as public interest grows.

Extracellular vesicles (EVs) have marked a significant shift in cancer research, introducing novel approaches for early diagnosis, targeted therapeutic delivery, and the development of personalized ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...